{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:44:19Z","timestamp":1793933059243,"version":"4.8.0"},"reference-count":30,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["HTA 14\/192\/89"],"award-info":[{"award-number":["HTA 14\/192\/89"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2022,5,12]]},"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To estimate the incidence and HRs for bleeding for different dual antiplatelet therapies (DAPT) in a real-world population with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) in England.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A retrospective, population-based cohort study emulating a target randomised controlled trial (tRCT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data sources<\/jats:title>\n                  <jats:p>Linked Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Primary and secondary care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Patients \u226518 years old with ACS undergoing emergency PCI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interventions<\/jats:title>\n                  <jats:p>Aspirin and clopidogrel (AC, reference) versus aspirin and prasugrel (AP) or aspirin and ticagrelor (AT); AP evaluated only in patients with ST-elevation myocardial infarction (STEMI).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>Primary: any bleeding up to 12 months after the index event (HES- or CPRD- recorded). Secondary: HES-recorded bleeding, CPRD-recorded bleeding, all-cause and cardiovascular mortality, mortality from bleeding, myocardial infarction, stroke, additional coronary intervention and major adverse cardiovascular and cerebrovascular events (MACCE).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In ACS, the rates of any bleeding for AC and AT were 89 per 1000 person years and 134 per 1000 person years, respectively. In STEMI, rates for AC, AP and AT were 93 per 1000 person years, 138 per 1000 person years and 143 per 100 person years, respectively. In ACS, compared with AC, AT increased the hazard of any bleeding (HR: 1.47, 95% CI 1.19 to 1.82) but did not reduce MACCE (HR: 1.06, 95% CI 0.89 to 1.27). In STEMI, compared with AC, AP and AT increased the hazard of any bleeding (HR: 1.77, 95% CI 1.21 to 2.59 and HR: 1.50, 95% CI 1.10 to 2.05, respectively) but did not reduce MACCE (HR: 1.10, 95% CI 0.80 to 1.51 and HR: 1.21, 95% CI 0.94 to 1.51, respectively). Non-adherence to the prescribed DAPT regimen was 28% in AC (29% in STEMI only), 31% in AP (STEMI only) and 33% in AT (32% in STEMI only).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In a real-world population with ACS, DAPT with ticagrelor or prasugrel are associated with increased bleeding compared with DAPT with clopidogrel.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN76607611\">ISRCTN76607611<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2022-001999","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T10:41:12Z","timestamp":1660300872000},"page":"e001999","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a \u2018target trial\u2019"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"isrctn76607611","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1775-1949","authenticated-orcid":false,"given":"Maria","family":"Pufulete","sequence":"first","affiliation":[{"name":"Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK"},{"name":"Bristol Heart Institute, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Harris","sequence":"additional","affiliation":[{"name":"Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Pouwels","sequence":"additional","affiliation":[{"name":"Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barney C","family":"Reeves","sequence":"additional","affiliation":[{"name":"Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lasserson","sequence":"additional","affiliation":[{"name":"Warwick Medical School, University of Warwick, Coventry, UK"},{"name":"Department of Geratology\/AGM, Oxford University Hospitals NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon K","family":"Loke","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia, Norfolk, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mumford","sequence":"additional","affiliation":[{"name":"School of Cellular and Molecular Medicine, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9414-6945","authenticated-orcid":false,"given":"Kalaivani","family":"Mahadevan","sequence":"additional","affiliation":[{"name":"School of Cellular and Molecular Medicine, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W","family":"Johnson","sequence":"additional","affiliation":[{"name":"School of Cellular and Molecular Medicine, Bristol Medical School, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"2025081612082818000_9.2.e001999.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000404"},{"key":"2025081612082818000_9.2.e001999.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419"},{"key":"2025081612082818000_9.2.e001999.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"2025081612082818000_9.2.e001999.4","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025081612082818000_9.2.e001999.5","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013679","article-title":"Bleeding after hospital discharge following acute coronary syndrome: incidence, types, timing, and predictors","volume":"8","author":"Ismail","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025081612082818000_9.2.e001999.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023337"},{"key":"2025081612082818000_9.2.e001999.7","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2025081612082818000_9.2.e001999.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"2025081612082818000_9.2.e001999.9","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2025081612082818000_9.2.e001999.10","unstructured":"Hospital episode statistics (Hes). Available: http:\/\/content.digital.nhs.uk\/hes"},{"key":"2025081612082818000_9.2.e001999.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029388"},{"key":"2025081612082818000_9.2.e001999.12","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta8400","article-title":"Clopidogrel used in combination with aspirin compared with aspirin alone in the treatment of non-ST-segment-elevation acute coronary syndromes: a systematic review and economic evaluation","volume":"8","author":"Main","year":"2004","journal-title":"Health Technol Assess"},{"key":"2025081612082818000_9.2.e001999.13","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2009.01.070282"},{"key":"2025081612082818000_9.2.e001999.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"2025081612082818000_9.2.e001999.15","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-016-0400-6"},{"key":"2025081612082818000_9.2.e001999.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-003389"},{"key":"2025081612082818000_9.2.e001999.17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(20)30930-2","article-title":"Invasive versus non-invasive management of older patients with non-ST elevation myocardial infarction (SENIOR-NSTEMI): a cohort study based on routine clinical data","volume":"396","author":"Kaura","year":"2020","journal-title":"Lancet"},{"key":"2025081612082818000_9.2.e001999.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.10.004"},{"key":"2025081612082818000_9.2.e001999.19","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2025081612082818000_9.2.e001999.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2006.00139.x"},{"key":"2025081612082818000_9.2.e001999.21","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/DDDT.S196535","article-title":"Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis","volume":"13","author":"Fan","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"2025081612082818000_9.2.e001999.22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012978","article-title":"Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: a systematic review and meta-analysis (2007-2017)","volume":"97","author":"Guan","year":"2018","journal-title":"Medicine"},{"key":"2025081612082818000_9.2.e001999.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.046786"},{"key":"2025081612082818000_9.2.e001999.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908973"},{"key":"2025081612082818000_9.2.e001999.25","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.amjcard.2020.03.019","article-title":"Meta-Analysis Comparing P2Y\n                  12\n                Inhibitors in Acute Coronary Syndrome","volume":"125","author":"Baldetti","year":"2020","journal-title":"Am J Cardiol"},{"key":"2025081612082818000_9.2.e001999.26","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/eurheartj\/ehx175","article-title":"Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the topic (timing of platelet inhibition after acute coronary syndrome) randomized study","volume":"38","author":"Cuisset","year":"2017","journal-title":"Eur Heart J"},{"key":"2025081612082818000_9.2.e001999.27","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015990","article-title":"Ticagrelor is not superior to clopidogrel in patients with acute coronary syndromes undergoing PCI: a report from Swedish coronary angiography and angioplasty registry","volume":"9","author":"V\u00f6lz","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025081612082818000_9.2.e001999.28","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1513\/AnnalsATS.201903-241OC","article-title":"Emulating a novel clinical trial using existing observational data. predicting results of the prevent study","volume":"16","author":"Admon","year":"2019","journal-title":"Ann Am Thorac Soc"},{"key":"2025081612082818000_9.2.e001999.29","doi-asserted-by":"publisher","DOI":"10.1177\/0962280211403603"},{"key":"2025081612082818000_9.2.e001999.30","unstructured":"Reeves BC , Deeks JJ , Higgins JPT . Chapter 13: Including non-randomized studies. In: Higgins JPT , Green S , eds. Cochrane Handbook for systematic reviews of interventions. version 5.0.2. The Cochrane Collaboration, 2009."}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2022-001999","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T19:08:41Z","timestamp":1755371321000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2022-001999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,8,12]]},"published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1136\/openhrt-2022-001999"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2022-001999","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}